Tailoring duration of DAPT with risk scores

The Lancet

Volumn 389, Issue 10073, 2017, Pages 987-989

  Capodanno, Davide ^a   Angiolillo, Dominick J ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATININE; HEMOGLOBIN; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL DECISION MAKING; DUAL ANTIPLATELET THERAPY; HUMAN; LEUKOCYTE COUNT; NOMOGRAM; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SMARTPHONE; TREATMENT DURATION; VASCULAR ACCESS; DRUG ELUTING STENT;

DRUG-ELUTING STENTS; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 85015231534     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30591-3     Document Type: Note

References (9)

1. 1 Bittl, JA, Baber, U, Bradley, SM, Wijeysundera, DN, Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 134 (2016), e156–e178.
2. 2 Levine, GN, Bates, ER, Bittl, JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg 152 (2016), 1243–1275.
3. 3 Windecker, S, Kolh, P, Alfonso, F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35 (2014), 2541–2619.
4. 4 Yeh, RW, Secemsky, EA, Kereiakes, DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315 (2016), 1735–1749.
5. 5 Baber, U, Mehran, R, Giustino, G, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol 67 (2016), 2224–2234.
6. 6 Costa, F, van Klaveren, D, James, S, et al., for the PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389 (2017), 1025–1034.
7. 7 Dauerman, HL, Rao, SV, Resnic, FS, Applegate, RJ, Bleeding avoidance strategies. Consensus and controversy. J Am Coll Cardiol 58 (2011), 1–10.
8. 8 Urban, P, Meredith, IT, Abizaid, A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 373 (2015), 2038–2047.
9. 9 Cook, NR, Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115 (2007), 928–935.